Key facts
- Neowise Biotechnology’s last known valuation is $229.1M (Oct 2025).
- It has raised $57.1M; the latest was Later Stage VC ($28.1M) in Oct 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Baidu Ventures, Leader Venture Capital, Beijing Delian Yuntong Investment Management Company, Marathon Venture Partners — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Neowise Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Neowise Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neowise Biotechnology
Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors. The company offers an antigen-antigen receptor pairing database to efficiently screen for suitable targets and receptor sequences for the treatment of solid tumors, followed by editing, amplification, and functional characterization of T cells, and the return of T cells with high specificity that recognize the patient's tumor surface antigens, providing cancer patients with tumor treatment.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- neowisebio.com/
- Ownership
- Privately Held (backing)
Neowise Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neowise Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neowise Biotechnology in its N-PORT filings yet. We sweep new filings monthly.